ResMed Inc. (RMD) Downgraded to Neutral by Citigroup

Market Context

ResMed Inc. operates in the Healthcare sector. The stock currently trades at $199.00 with a market capitalization of $37.0B. The stock has declined 18.9% over the past 52 weeks.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Citigroup's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for ResMed Inc.

Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 13, 2026	Citigroup	Neutral	N/A
Jul 10, 2026	Jefferies	Hold	N/A
Jul 08, 2026	RBC Capital	Outperform	N/A
Jul 08, 2026	Wells Fargo	Equal-Weight	N/A
Jun 22, 2026	Keybanc	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View RMD Stock Page